Longeveron® Announces Full-Year 2024 Financial Results and Provides Business Update
Provided By GlobeNewswire
Last update: Feb 28, 2025
MIAMI, Feb. 28, 2025 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions, today reported financial results for the full-year ended December 31, 2024 and provided a business update.
Read more at globenewswire.com
